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Background:  School-based  inﬂuenza  immunization  can  effectively  address  accessibility  barriers,  but
injected inactivated  inﬂuenza  vaccines  (IIV)  may  not  be acceptable  to  some  children  and  parents  in
school  settings.
Objectives:  To better  understand  the feasibility  of  offering  intranasal  live  attenuated  inﬂuenza  vaccines
(LAIV)  through  schools,  we assessed  uptake,  stakeholder  acceptability,  and cost  of  school-based  delivery
of LAIV  compared  to IIV.
Methods:  We  piloted  an  open-label  cluster  randomized  trial involving  10 elementary  schools  in  Peter-
borough,  Ontario  during  the  2013–2014  inﬂuenza  vaccination  campaign.  Schools  were  randomized  to
having  students  receive  IIV  or LAIV at publicly-funded  school-based  clinics  organized  by the  local  pub-
lic  health  department.  We  measured  the  percentage  of  students  vaccinated  with  at least  one  dose  of
inﬂuenza  vaccine  at school.  Stakeholder  acceptability  was evaluated  through  a questionnaire  of  parents
and  interviews  of  public  health  department  personnel  and school  principals.  We  compared  the  costs  per
dose  of  vaccine  administered,  including  staff  time  and  costs  of  vaccines  and  supplies.
Results:  Single-dose  inﬂuenza  vaccine  uptake  was  higher  for the  ﬁve  schools  offering  LAIV  than  for  the
ﬁve  offering  IIV  (19.3%  vs.  12.2%,  p = 0.02).  Interviews  with  nine  school  principals  and  ﬁve public health
department  personnel  suggested  that the clinics  ran  smoothly  with little  disruption  to school  routines,
and  that  LAIV  was  associated  with  increased  efﬁciency  and  calmer  children.  All  interviewees  cited  unfa-
miliarity  with  LAIV  and the  study  recruitment  package  length  as potential  reasons  for  low  uptake.  The
cost  per  vaccine  dose  administered  was $38.67  for  IIV and  $43.50  for  LAIV.
Conclusions:  Use  of  LAIV  in  school-based  clinics  was  associated  with  increased  vaccine  uptake  and  the  per-
ception  among  immunizing  staff  of  reduced  child  anxiety,  but  also  slightly  higher  vaccine  administration
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uay,  Jeff Kwong, Allison McGeer, Jennifer Pereira, Susan Quach, Sherman Quan, and Margaret L. Russell.
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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costs,  compared  to  IIV.  However,  uptake  was  low  for  both  groups.  More  effective  strategies  to  promote
inﬂuenza  vaccines  and to obtain  parent  consent  may  improve  vaccine  uptake.
Trial registration:  ClinicalTrials.gov  NCT01995851.
Funding: Public  Health  Agency  of  Canada/Canadian  Institutes  of  Health  Research  Inﬂuenza  Research  Net-
work.
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. Introduction
Seasonal inﬂuenza causes increased mortality, health services
tilization, and work and school absenteeism every year [1–5].
ntario, Canada’s most populous province, introduced universal
ublicly funded inﬂuenza immunization in 2000, offering free
nﬂuenza vaccines for all individuals aged 6 months or older [6].
hese are accessible through institutions (e.g. hospitals, long-term
are facilities), physician ofﬁces, public health-organized clinics,
orkplace clinics, and pharmacies. Vaccinating children may  be
n effective strategy for inﬂuenza control because of their high
nﬂuenza attack rates [7–9]. However, despite the availability
f free immunization, during the 2006–2007 inﬂuenza season,
nﬂuenza vaccine coverage was only 31% among children aged
2–19 years, 28% among healthy children aged 2–11 years, and 37%
mong children aged 2–11 years with chronic health conditions
10], far lower than the >70% coverage observed among adults aged
5 years or older [11]. One reason for not being immunized is hav-
ng barriers to access, such as lack of transportation and personal
nd family responsibilities [12–14].
Analogous to established Ontario-wide public health pro-
rams providing vaccinations against hepatitis B virus, human
apillomavirus, and meningococcal disease through schools [15],
chool-based inﬂuenza immunization has been considered as a
trategy to overcome access barriers. Since 2000, it has been
mplemented at the discretion of each of Ontario’s 36 pub-
ic health departments, and has been associated with increased
overage and decreased physician visits among school age
hildren [11]. Ontario parents appreciate the potential con-
enience of immunizing children against inﬂuenza at school
ut retain several concerns including children being afraid
f needles and requiring parental comfort during vaccination
16].
Live attenuated inﬂuenza vaccine (LAIV) is an alternative to
njected inactivated inﬂuenza vaccines (IIV). LAIV was  approved for
se in the United States in 2003 and in Canada in 2010. Canada’s
ational Advisory Committee on Immunization recommends it
ver IIV for healthy children between 2 and 17 years, based on
mmunogenicity, efﬁcacy, and effectiveness data in young chil-
ren [17]. A meta-analysis of three clinical trials involving 13,000
ealthy children aged 6 months to 17 years demonstrated that
ompared to IIV, receipt of LAIV reduced the risk of laboratory-
onﬁrmed inﬂuenza by 45–53% in vaccine-naïve children (6 to 71
onths) and 35% in previously vaccinated older children (6–17
ears) [18]. Providing LAIV through schools has been associated
ith increased coverage and decreased inﬂuenza-like illness in
chool age children [9,19]. However, at this time in Ontario, only
IV is publicly funded. The use of LAIV as part of the province’s
niversal inﬂuenza immunization program is currently under
eview.
We conducted a pilot study to evaluate the feasibility of
dministering LAIV vs. IIV via schools by determining the effect
f inﬂuenza vaccine type on uptake, stakeholder acceptabil-
ty, and cost. Since the intervention is at the level of the
chool, with the hypothesis that providing LAIV to children at
chool will lead to increased vaccine uptake, we used a cluster
esign.hed  by Elsevier  Ltd. This  is  an  open  access  article  under  the  CC BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
2. Methods
During the 2013–2014 inﬂuenza vaccination campaign, we
conducted an open-label cluster randomized trial involving ele-
mentary schools (Junior Kindergarten [age 4] to Grade 8 [age 13])
within the geographic boundaries of the Peterborough County-City
Public Health Unit (PCCHU). This local public health department
is responsible for a mixed urban-rural community (population
∼145,000) 125 km northeast of Toronto, Ontario. In September
and October 2013, 10 of 28 schools belonging to the Kawartha
Pine Ridge District School Board agreed to participate. Participat-
ing schools and non-participating schools were similar in rural
representation (40% vs. 44% of all schools, respectively, with rural
location deﬁned as having a zero in the second position of their
6-digit postal code, indicating an area that is not accessible by
letter carriers) [20]. Using a standard computer pseudorandom
number generator, the schools were randomized by JAP on a
1:1 basis to having all students offered IIV or LAIV at publicly-
funded school-based inﬂuenza immunization clinics organized by
PCCHU.
In October 2013, 10-page recruitment packages comprising an
introductory letter, a study consent form, a vaccine consent form,
and a Frequently Asked Questions document were sent home with
all students. Parents/guardians (hereafter referred to as “parents”)
were requested to return the study consent form, and if they wished
to have their child/dependent (hereafter referred to as “children”)
vaccinated at school, the vaccine consent form as well. Each school
used at least two  promotional tools to inform parents of the study
(e.g., automated voice messages, email distribution lists, school
websites, school signs).
Between November 11 and 22, 2013, public health nurses con-
ducted an immunization clinic at each school for students for whom
parental consent had been obtained. At intervention schools, stu-
dents without contraindications to LAIV were immunized with a
0.2 ml  dose of intranasal LAIV (FluMist®) [17]. IIV was available for
children whose parents declined LAIV but still wanted their child
immunized against inﬂuenza. At control schools, students who did
not have a contraindication to IIV were immunized with a 0.5 ml
dose of intramuscular IIV (Vaxigrip®) [17]. The nurses returned
to each school within two weeks to vaccinate children who had
been absent during the ﬁrst clinic, or whose parents had forgot-
ten to submit their vaccine consent form. Children aged younger
than 9 years who had not previously received inﬂuenza vaccine
required two doses, however, the second dose was not adminis-
tered at school. Parents were instructed to have their child receive
the second dose at least four weeks after the ﬁrst dose via their
primary care physician or a community-based public health clinic.
All parents who  provided an email or mailing address on the
study consent form were contacted in February 2014 and invited
to complete an Internet- or paper-based questionnaire on behalf of
their children. The questionnaire asked about demographics, risk
factors for inﬂuenza, receipt of inﬂuenza vaccines during the cur-
rent inﬂuenza season, and adverse events following immunization.
Two reminders were sent out to parents who  had not yet com-
pleted a questionnaire (in two- or four-week intervals for emailed
and mailed questionnaires, respectively). Respondents received a
$5 Starbucks gift card as an incentive to complete the questionnaire.
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Assessed for eligibility 
 (n = 28 schools) 
Excluded because refused to 
participate (n =18 schools)
Randomized (n = 10 schools) 
Allocated to IIV 
(n = 5 schools, 1394 students, 
mean school size = 278.8 
students, variance of school
size = 11,005.8) 
Received allocated intervention 
(n = 5 schools, 170 students) 
Did not receive allocated 
intervention (n = 0 schools)
A
llo
ca
tio
n
En
ro
llm
en
t 
Allocated to LAIV
(n = 5 school, 1458 students, 
mean school size = 291.6 
students, variance of school
size = 17,519.4) 
Received allocated 
intervention (n = 5 schools,
279 students) 
Did not receive allocated
intervention (n = 0 schools)
Fo
llo
w
 u
p
Lost to follow up 
(n = 0 schools, 0 students) 
Discontinued intervention 
(n = 0 schools, 0 students) 
Lost to follow up 
(n = 0 schools, 0 students) 
Discontinued intervention
(n = 0 schools, 0 students) 
A
na
ly
sis
Analyzed (n = 5 schools,
170 students) 
Excluded from analysis 
 (n = 0 schools, 0 students )
Analyzed (n = 5 schools,
279 students) 
Excluded from analysis
(n = 0 schools, 0 students)J.C. Kwong et al. / Va
.1. Uptake
We  used the number of children who had received one dose
by vaccine type) of inﬂuenza vaccine given at school-based clinics
s the numerator, and the student census as of January 1, 2014
provided by each school) as the denominator, to calculate school-
evel vaccine uptake.
.2. Safety
As per public health guidelines, public health nurses moni-
ored children for 15 min  following vaccination. Parents/guardians
ere asked to contact the study team if their child experienced
ny symptoms during the following ﬁve days. Public health nurses
ollowed up with parents who reported an event. The study ques-
ionnaire also asked parents to indicate whether their child had
xperienced any adverse event in the 7 days following receipt of
nﬂuenza vaccine at school.
.3. Stakeholder acceptability
The stakeholders of interest were all parents with children
ttending these 10 schools, school principals of these schools, and
CCHU personnel who participated in the school-based clinics or
ssisted in organizing them. We  assessed parental perceptions
f school-based immunization with LAIV and IIV through the
uestionnaire, which included questions about perceived safety,
ffectiveness, and acceptability of inﬂuenza vaccines.
The school principals and PCCHU’s immunization program
anager and immunizing nurses were invited to participate in
ne-on-one telephone interviews with JAP. Interviews with school
rincipals focused on their experiences with coordinating the pro-
ram, facilitators/barriers to its continued existence, and relevant
nteractions with parents and teachers. Interviews with public
ealth personnel focused on perceptions of the program and of
dministration of IIV vs. LAIV, based on experiences with clinic
oordination and vaccine delivery.
.4. Cost
We  performed a cost comparison of school-based administra-
ion of IIV versus LAIV. The following costs were obtained from
CCHU: associated equipment (syringes, needles, alcohol wipes,
otton balls, plastic bandages, tissues), staff time spent on campaign
oordination, communication with parents/guardians at clinics,
accine delivery, and post-vaccination monitoring. Vaccines are
ulk purchased by Ontario’s Ministry of Health and Long-Term Care,
o the cost per dose of vaccine was obtained from the Ministry.
.5. Analysis
Continuous variables were compared using two sample t tests
nd proportions were compared using chi-square tests or Fisher’s
xact tests. To compare school-level vaccine uptake between the
wo arms, we performed a weighted t test to adjust for cluster-
ng and to take variation in student population size into account
21]. Two-sided tests were used for all statistical analyses. We  used
TATA version 10.0 (2007, StataCorp, LP, College Station, TX) for
nalyses.The interviews were reviewed to facilitate an exploration of
mergent themes [22]. At least two team members read each tran-
cript once to get an overall sense of the data, and then again to
dentify major topics or issues.Fig. 1. Enrollment and follow-up of study participants.
2.6. Sample size
To calculate the sample size required to detect a 10% increase
in uptake with LAIV compared to IIV, we used the sample size cal-
culation for two proportions based on 80% power and alpha = 0.05
(two-sided). The unit of randomization was the school. To account
for the clustering effect of schools, we inﬂated the sample size by
20% (i.e., variance inﬂation factor), resulting in a sample size of 451
students/group.
2.7. Ethics
This study was approved by Public Health Ontario’s Ethics
Review Board (Protocol 2013-24.04) and Kawartha Pine Ridge Dis-
trict School Board’s Research Advisory Committee.
3. Results
Of the 28 eligible schools, 10 study schools (total number of
students = 2852, range = 110–450 students per school) agreed to
participate and were randomized; 5 were assigned to receive LAIV
and 5 were assigned to receive IIV (Fig. 1).
Based on questionnaire responses from parents (response rates:
9.2% overall [262/2852], 7.7% [107/1394] for IIV schools, 10.6%
[155/1458] for LAIV schools), the demographics of the two groups
were similar (Table 1).
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Table 1
Characteristics of the study population obtained from a questionnaire of parentsa.
Responses from
IIVb schools:
n = 107 (%)d
Responses from
LAIVc schools:
n = 155 (%)d
Children’s characteristics
Female 54 (50.4) 79 (51.0)
Mean age (years) (standard
deviation, range)
8.1 (3.5, 4–13) 8.2 (3.4, 4–14)
Body mass index (BMI)e
Normal weight 67 (71.3) 101 (70.1)
Overweight 13 (13.8) 16 (11.1)
Obese 14 (14.9) 27 (18.8)
Has a regular doctor 103 (97.2) 155 (100)
Inhaled steroid use more than
twice weekly
2 (2.0) 4 (2.7)
Long term aspirin user 0 (0) 1 (0.7)
Has a chronic diseasef 7 (7.0) 15 (10.1)
Aboriginal status 3 (3.0) 6 (4.1)
Household members’
characteristics
Highest level of education attained
by household members
Less than high school 1 (1.0) 3 (1.9)
High school graduation 11 (10.6) 10 (6.5)
Post-secondary graduation 92 (88.5) 142 (91.6)
Household member with a
weakened immune system
10 (10.0) 9 (6.2)
Household has one or more
children aged 2 years or younger
10 (10.0) 26 (17.8)
Household member smokes 16 (15.8) 23 (15.9)
Children’s vaccination history
Vaccinated against inﬂuenza this
season (Oct 2013 to Feb 2014)
89 (83.2) 136 (87.7)
Vaccinated against inﬂuenza last
season (Oct 2012 to Feb 2013)
49 (51.6) 68 (50.0)
Vaccinated against inﬂuenza
before October 2012
64 (68.1) 101 (76.5)
Had a severe reaction to a previous
inﬂuenza vaccine
0 (0) 2 (1.4)
Had a negative reaction to any
vaccine
7 (6.9) 6 (4.0)
a The study population consists of all children whose parents completed a ques-
tionnaire, including those who  did not receive inﬂuenza vaccination at school.
b Inactivated inﬂuenza vaccine.
c Live attenuated inﬂuenza vaccine.
d Denominator of each response varies depending on completeness of data. Miss-
ing data and “don’t know” responses were excluded from the analysis.
e BMI categories for children are based on the 2000 US Centers for Disease Control
a
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Table 2
Single dose inﬂuenza vaccine uptake by type of vaccine offered at each school.
School Number
vaccinated
School
population
Single dose vaccine
uptake (%)
IIVa 1 20 110 18.2
IIV  2 42 300 14.0
IIV  3 14 230 6.1
IIV 4 51 424 12.0
IIV  5 43 330 13.0
IIV  Total 170 1394 12.2
LAIVb 1 93 450 20.7
LAIV 2 35 280 12.5
LAIV 3 17 117 14.5
LAIV 4 35 180 19.4
LAIV 5 99 431 23.0
LAIV Total 279 1458 19.3
If both vaccines were offered for free next year, parents at LAIV
schools were more likely than parents at IIV schools to prefer their
Table 3
Parental vaccination behaviours and attitudes.
Behaviour or attitude (in reference to the 2013–2014 inﬂuenza
season)
n (%)a
Vaccination status of respondent’s child (n = 261)
Received IIVb 92 (35.3)
Received LAIVc 132 (50.6)
Did not receive any inﬂuenza vaccine 37 (14.2)
Reasons child was not vaccinated against inﬂuenza (n = 37)
Did not feel it was  necessary 23 (62.1)
Concerned about negative side effects 14 (37.8)
I  don’t believe the vaccine is effective 12 (32.4)
Have not gotten around to it 3 (8.1)
Not convenient 1 (2.7)
The child is not eligible to receive the vaccine 1 (2.7)
Reasons child received inﬂuenza vaccine at school (n = 157)
Convenience of school vaccination 124 (79.0)
School offered LAIV vaccine at no cost 92 (58.6)
Parent/guardian works full-time 27 (17.2)
Not sure where else to get child vaccinated 8 (5.1)
Child is better receiving vaccinations when parent is absent 7 (4.5)
Child preferred to be vaccinated with friends 4 (2.6)
Preferred non-injection vaccine over injection 3 (1.9)
No access to a car 1 (0.6)
Reasons child received inﬂuenza vaccine outside of school
(n  = 11)
Parent wanted to be present while child was  vaccinated 4 (36.4)
Parent wanted child to be vaccinated earlier than the school
date
1 (9.1)
Parent did not want child to receive the vaccine offered at
school
1 (9.1)
Parent would prefer child to be vaccinated by own healthcare
provider
1  (9.1)
Child was  absent on the vaccination day 1 (9.1)
None 2 (18.2)nd  Prevention Growth Reference.
f Chronic diseases included: asthma, diabetes, cancer, anaemia, heart disease,
ung disease, kidney disease, blood diseases.
.1. Uptake
LAIV-assigned schools had signiﬁcantly higher single-dose
ptake (279/1458; 19.3%, 95%CI 14.1–24.5%) than IIV-assigned
chools (170/1394; 12.2%, 95%CI 7.8–16.5%) (difference = 7.2%,
5%CI 1.5–12.8%; p = 0.02) (Table 2).
.2. Safety
No signiﬁcant difference in the proportion of side effects expe-
ienced for children receiving IIV vs. LAIV (8.8% vs. 11.3%, p = 0.62)
as observed.
.3. Acceptability
.3.1. Parents
Parents cited various reasons for having or not having their
hildren vaccinated at school (Table 3). Some questionnaire
espondents did not consent to school-based immunization for
heir children. Of the 37 children whose parents returned aa Inactivated inﬂuenza vaccine.
b Live attenuated inﬂuenza vaccine.
questionnaire but did not receive vaccine at school clinics, 18
attended IIV schools and 19 attended LAIV schools. Fifteen of the 37
children were vaccinated in other settings: physician ofﬁces (n = 6),
public health community-based clinics (n = 5), pharmacies (n = 3),
and workplace clinics (n = 1).
Only 28.4% of all respondents were familiar with LAIV prior
to the 2013–2014 inﬂuenza season. A signiﬁcantly higher propor-
tion of parents of children attending LAIV schools thought LAIV
was more effective at preventing inﬂuenza than IIV (26.9% vs. 0%,
p < 0.001) and was safer than IIV (26.9% vs. 9.6%, p = 0.003) (Table 4).a The percentages for some questions may  add up to greater than 100% because
respondents could select more than one response.
b Inactivated inﬂuenza vaccine.
c Live attenuated inﬂuenza vaccine.
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Table  4
Comparison of parents’ vaccine preferences based on school allocation.
Question Responses
from IIV
schools, n (%)
Responses
from LAIV
schools, n (%)
Which vaccine do you think is more
effective at preventing inﬂuenza in
kids? (n = 202)
LAIV 0 32 (26.9)
IIV 10 (12) 3 (2.5)
No difference 16 (19.3) 35 (29.4)
Neither are effective 1 (1.2) 0
Don’t know 56 (67.5) 49 (41.2)
Which vaccine do you think is safer
for kids? (n = 202)
LAIV 8 (9.6) 32 (26.9)
IIV 8 (9.6) 5 (4.2)
No difference 23 (27.7) 45 (37.8)
Neither are effective 2 (2.4) 1 (0.8)
Don’t know 42 (50.6) 36 (30.3)
aWhich vaccine do you feel more
comfortable with your child
receiving (n = 261)?
LAIV 17 (15.9) 90 (58.4)
IIV 19 (17.8) 7 (4.5)
No difference 50 (46.7) 36 (23.4)
Neither vaccine 15 (14.0) 19 (12.3)
Don’t know 6 (5.6%) 2 (1.3)
aWhich vaccine would you prefer
your child receive next year,
assuming both vaccines are
available for free (n = 260)?
LAIV 35 (32.7) 111 (72.5)
IIV 19 (17.8) 6 (3.9)
No preference 30 (28.0) 19 (12.4)
Neither vaccine 14 (13.1) 14 (9.2)
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“My general feelin g is  that [LAIV  cli nics] went  very  well, ve ry smoothly,  better  th an injection, we  
had  very few of  the sw ooners  th at we usually get.  I can almost  predi ct which kids  it’s  go nna be. I was 
really impresse d wi th how  it  ra n th at day.  I ho pe to see it  become  so mething of  a reg ular pr actice.”
(Principal 3) 
 “I  think wit h our  population it’s  har d…they  do n’t  have time  for  cons ent for ms,  and we  try  to 
send out  forms  th at are 1,  maybe  2 pages max.  Otherwise,  they have no time  for  al l of th at.”  (Princ ipal 1) 
“I don’ t thin k school’s  the place for  [S BII clinics]. It’s  just  not  a good place  for  vac cines.  We’re 
not  equip ped for it.  The ki ds get  so  upset!  Some don’ t ev en know  what’s  going  to  happen,  their parents 
didn’t tell them so they’re crying and upset, and it lasts all day. We’re a school, we can’t provide the 
comfort…  we can’t do the parenting. And  I think a lot of our  parents  want  us to do the  parenti ng,  they 
don’ t wa nt to be  there  for th at, they kn ow th eir child wil l be ups et so they’ d rather  we  de al with  it. But 
we’re a school, we’re not equipped to handle it.” (Principal 6) 
“I wo uld say  most of  the kids  were  very  accept ing of the  nas al mist.  Much more so th an of the  injectio n... 
And [LAIV] was faster... You don’t have as much getting ready with that” (Nurse 3) Don’t know 9 (8.4) 3 (2.0)
a Parents could respond more than once if they had more than one child.
hild receive LAIV (72.5% vs. 32.7%, p < 0.001), while the opposite
attern was observed for IIV (3.9% vs. 17.8%, p < 0.001).
Of the 259 parents who responded to our question about com-
ort with vaccine, 46 (17.8%) were uncomfortable with their child
eceiving LAIV; reasons included insufﬁcient safety data (40.5%),
elief that the vaccine is unnecessary (38.1%), and their child hav-
ng no issues with IIV injection (33.3%). However, 53 (20.5%) of those
59 parents were uncomfortable with their child receiving IIV, with
he main reason being the child’s fear of needles (43.4%).
.3.2. Principals
Nine of 10 school principals (one IIV principal declined to
espond) were interviewed. The principals reported that school
esponsibilities during the clinics involved brieﬁng teachers about
he study, disseminating recruitment packages, reminding stu-
ents to return forms, and implementing promotional activities.
ll principals stated that the clinics required minimal time com-
itment from school staff.
Seven principals indicated that their school’s teachers expressed
isappointment that staff could not be vaccinated at the school clin-
cs. One principal from an IIV school reported that staff thought
hat the recruitment package was too large and complex for their
tudents’ parents (Fig. 2).
One principal from an IIV school recounted that a parent
xpressed concern that their child was being asked to try an
ntested vaccine. This principal felt that the word “study” may  have
mplied that the vaccines’ safety and efﬁcacy were unproven.
All nine principals found the nursing staff to be very efﬁcient
ith clinic processes. Principals at LAIV schools were particularly
mpressed, with three remarking on how the children seemed
almer than they do after receiving injectable vaccines at school
e.g., hepatitis B virus and human papillomavirus vaccines). ToFig. 2. Quotes from stakeholders regarding school-based inﬂuenza immunization.
increase vaccine uptake, the principals recommended more pro-
motion at the beginning of the school year, so that parents would
be aware that the clinic was upcoming, and also be able to gain
more familiarity with LAIV.
All principals understood that study materials had to contain
more information than typical consent forms, but agreed that
school forms should not exceed three pages. Three principals men-
tioned that their schools’ families were of a low socioeconomic
status, and were unlikely to read lengthy, text-heavy documents.
One principal suggested that an abbreviated two-page package be
developed to send home to every parent, advising them to pick
up the full-sized package from the principal’s ofﬁce should they
require additional information.
Principals generally thought that school-based inﬂuenza immu-
nization is a good idea, and should continue, with the option for staff
to be vaccinated. One principal wished to make his school a com-
munity hub, and thought the clinic should be open to the public.
However, one principal at an IIV school thought that school-based
clinics interfered with education, and that children with anxiety
over needles often required comfort that teachers are unable to
provide.
3.3.3. Public health department personnel
Individual telephone interviews were conducted with the
immunization program nurse-manager and four of the ﬁve immu-
nizing nurses (the ﬁfth nurse was out-of-town and could not be
contacted). The nurse responsible for scheduling the clinics stated
that this process was  very similar to the coordination that she does
for other school-based immunization clinics, and it was facilitated
by the mutual familiarity between her and school representatives.
All ﬁve of the nurses were satisﬁed with the clinics’ organiza-
tion, and they perceived that the LAIV clinics ran more quickly than
IIV clinics due to less time required to reassure children and not
needing to remove layers of clothing to administer vaccine. Two
nurses perceived that children were calmer after LAIV administra-
tion compared to vaccination with IIV.
To improve uptake, the nurses suggested that vaccine promo-
tion campaigns should begin earlier in the school year and to use
media (radio and television) to provide information on the vac-
cines and clinic schedules. The nurses thought that the length of the
recruitment packages likely served as a deterrent for participation.
They heard from a few parents who were very satisﬁed with LAIV,
since their children seemed to accept it much better than a nee-
dle. One interviewee mentioned that using electronic methods as
an option for obtaining consent might be beneﬁcial, since children
may  not bring back signed forms.
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Table 5
Cost per vaccine dose administered.
Item IIVa LAIVb
Vaccine $10.00 $20.00
Clerical staff time $16.10 $16.10
Nursing staff time $12.00 $7.30
Cotton ball $0.005 N/A
Alcohol pads $0.02 N/A
Needle/syringe $0.42 N/A
Bandage $0.13 N/A
Total $38.67 $43.40
3
$
4
i
b
t
(
w
H
f
a
i
t
s
o
o
P
s
n
w
a
m
m
w
t
i
m
m
e
o
c
l
s
o
d
b
R
s
t
v
o
s
a
ta Inactivated inﬂuenza vaccine.
b Live attenuated inﬂuenza vaccine.
.4. Cost
The cost per dose of vaccine administered was $38.67 for IIV and
43.40 for LAIV (Table 5).
. Discussion
This pilot study was conducted to better understand the feasibil-
ty of offering LAIV through schools, by comparing it to IIV delivery
ased on uptake, acceptability, and cost. LAIV uptake was  higher
han that for IIV, the main stakeholders of school-based clinics
parents, school principals, and immunization staff) were pleased
ith the process, and cost was comparable between the two  arms.
owever, overall uptake was lower than expected, suggesting that
urther work is required to increase vaccine awareness in parents
nd to provide education regarding vaccine safety and efﬁcacy.
We observed lower uptake than in recent school-based LAIV
mmunization studies in the UK and the US [9,23], possibly due
o the length of the study recruitment package, the timing of the
chool clinics, and the availability of inﬂuenza vaccines through
ther settings. However, without conﬁrmation from parents who
pted out of the study, we cannot verify these explanations.
CCHU’s typical vaccine consent forms are two pages or fewer but
ince this was a research study, and we assumed that parents had
ot previously heard of LAIV, it was necessary to provide them
ith additional information. We  offered each school the option of
 parent information session, but principals preferred other pro-
otional activities. PCCHU could not schedule the clinics before
id-November due to competing priorities, but parents may  have
anted their children vaccinated earlier in the season. In addition
o physician ofﬁces and community-based public health clinics,
nﬂuenza vaccines became available for the ﬁrst time in phar-
acies in Peterborough during the 2013–2014 inﬂuenza season,
aking vaccines more accessible for families who may  have oth-
rwise opted for school-based vaccination. We  also heard from
ne nurse and one principal that offering a second school-based
linic in January would be beneﬁcial, to capitalize on the estab-
ished pattern of inﬂuenza vaccination rates plateauing until a
econd wave of vaccination requests is prompted by media reports
f serious inﬂuenza complications (e.g., an inﬂuenza-related
eath).
The difference in uptake between IIV and LAIV schools may
e partially explained by LAIV being offered for free in the study.
esults from our questionnaire indicate that this was  a key rea-
on why parents of children at LAIV schools opted for vaccination
hrough the school. Parents who wished to have their children
accinated with LAIV would have had to pay for the vaccine
utside of the study, whereas IIV is offered for free through univer-
al publicly funded vaccination. The variations in vaccine uptake
cross all IIV and LAIV schools may  be due to the varying promo-
ional activities used at each school. Since they each had different33 (2015) 535–541
pre-existing communication channels to alert parents to the study,
we could not implement a consistent promotional plan across all
schools.
Although IIV is a less costly vaccine than LAIV, when the costs
related to vaccine administration are included, the overall cost per
dose is comparable. More nursing hours are required with IIV, since
time is spent removing layers of clothing to access the upper arm
and convincing anxious children to receive a needle. The trade-off
is that LAIV has more contraindications, so that nurses spend more
time asking questions and conﬁrming information.
Overall clerical and vaccine administration costs were likely
higher for this study than for regular inﬂuenza vaccination clin-
ics, due to the additional tasks involved (e.g., study record-keeping,
follow-up with parents whose children had a minor adverse event
following vaccination). Our results are aligned with a recent Cana-
dian study that modelled the cost-effectiveness of LAIV and IIV
for children aged 2–17 years and found LAIV to be associated
with higher vaccination costs than IIV [24]. However, due to fewer
anticipated inﬂuenza cases leading to reduced healthcare use and
parents’ work absenteeism, LAIV saved $4.20 and $35.34 per vac-
cinated child in direct and societal costs, respectively, compared to
IIV.
Although LAIV has been used in the US since 2003, and has
been approved in Canada since 2010, the questionnaire responses
suggest that parents in Ontario are not familiar with it, which
is to be expected since it is not publicly funded. Asking parents
to consent to their children receiving an unfamiliar vaccine may
have fostered the erroneous perception that we were studying a
new and untested drug. The results of this study demonstrate that
experience with LAIV is generally positive; parents who had their
children vaccinated with LAIV were likely to believe it is safe and
effective, and to feel comfortable with their child receiving it in
the future. In a 2012 German study of 146 children vaccinated
with LAIV, parents gave LAIV a mean acceptability rating of 1.55
(1 = very good, 6 = unacceptable), and 140 (97%) parents indicated
they would opt for their child to receive LAIV again the following
year [25].
Our interviews found that principals and nurses perceived that
children were calmer after receiving LAIV than they typically are
following receipt of an injectable vaccine. Although we did not
obtain children’s perceptions in this study, these observations cor-
roborate a 2011 survey of US children aged 8–12 years that found
nearly 70% preferred receiving inﬂuenza vaccine as an intranasal
spray compared to an injection, and that mode of administration
had the greatest impact on personal preference compared to other
vaccine attributes [26].
This study had some limitations. This was an open-label trial,
which could have introduced bias due to free availability of IIV
but not LAIV outside of the study. We  did not blind schools or
students because we  did not think using placebo injections and
nasal sprays would be feasible. Vaccine uptake was lower than
anticipated, which may  have been partially due to the relatively
late timing of the school-based immunization clinics. Although
inﬂuenza vaccines were available to the public in early October, the
local public health department was  only able to conduct the school
clinics in November because their nursing staff were already com-
mitted to school-based immunization clinics for other vaccines. The
timing of school-based inﬂuenza immunization has been shown to
be associated with uptake obtained [27]. Our questionnaire had a
low response rate (9%), with most respondents being parents who
had their child vaccinated. These parents could have been more
informed about the beneﬁts of vaccination or are more likely to
seek preventive healthcare services compared to those who refuse
vaccination, therefore the results from the questionnaire may  be
biased. Also, the information provided to parents focused on the
vaccine to which their children’s school was assigned (e.g., parents
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t LAIV schools were informed that LAIV is more effective than IIV),
hich likely impacted their perceptions of the vaccines. Since we
elivered information to parents by having students take paper
ecruitment packages home, we do not know if parents did not
eceive the package, they did not read it, they did not want to
articipate, or if students did not return the signed study consent
orms (with the parent contact information for the questionnaire)
o their teachers. Other studies have shown that parents perceive
t important that multiple methods be used to deliver information
nd consent forms [28]. Furthermore, parents may  have been con-
used by the inclusion of a study consent form requesting contact
nformation for the questionnaire and a separate vaccine adminis-
ration consent form. Separating delivery of the two consents may
ave increased the response from parents interested in providing
pinions via a questionnaire but who did not want their children
o be vaccinated at school. Finally, our survey respondents are not
ecessarily representative of the Ontario population as they were
ore likely to have their children vaccinated, but the results con-
erning acceptability from the school principals and public health
epartment personnel should be transferable to other settings.
. Conclusion
Our pilot study demonstrated that LAIV can be administrated in
chool clinics in an efﬁcient manner with high stakeholder accept-
bility and comparable costs to IIV administration. Further work is
equired to increase uptake, including parental education, promo-
ion of vaccine clinics at the start of the school year, and employing
oth online and paper-based methods to distribute information to
arents.
The full trial protocol may  be requested from the authors.
onﬂict of interest statement
None declared.
cknowledgements
We  wish to thank the Ontario Ministry of Health and Long-Term
are, the Peterborough County-City Health Unit, the Kawartha Pine
idge District School Board, the principals and teachers at the par-
icipating schools, and especially the students and their parents
or their participation in this study. This study was  supported by
n operating grant from the Public Health Agency of Canada and
he Canadian Institutes of Health Research (CIHR) (PIR 124309). Dr.
wong was supported by a CIHR New Investigator Award and a Uni-
ersity of Toronto Department of Family and Community Medicine
linician Scientist Award. The Canadian Association for Immuniza-
ion Research and Evaluation provided networking assistance.
eferences
[1] Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating inﬂuenza
deaths in Canada, 1992–2009. PLoS One 2013;8(11):e80481.
[2] Schanzer DL, Schwartz B. Impact of seasonal and pandemic inﬂuenza on
emergency department visits, 2003–2010, Ontario, Canada. Acad Emerg Med
2013;20(4):388–97.
[3] Schanzer DL, Zheng H, Gilmore J. Statistical estimates of absenteeism
attributable to seasonal and pandemic inﬂuenza from the Canadian Labour
Force Survey. BMC  Infect Dis 2011;11(90) (2334-11-90).
[
[33 (2015) 535–541 541
[4] Schanzer DL, Langley JM,  Tam TW.  Role of inﬂuenza and other respiratory
viruses in admissions of adults to Canadian hospitals. Inﬂuenza Other Respir
Viruses 2008;2(1):1–8.
[5] Schanzer DL, Langley JM,  Tam TW.  Hospitalization attributable to inﬂuenza
and  other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J
2006;25(9):795–800.
[6] Kwong JC, Stukel TA, Lim J, McGeer AJ, Upshur RE, Johansen H, et al. The effect of
universal inﬂuenza immunization on mortality and health care use. PLoS Med
2008;5(10):e211.
[7] Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ.  Assessing
optimal target populations for inﬂuenza vaccination programmes: an evidence
synthesis and modelling study. PLoS Med  2013;10(10):e1001527.
[8] Loeb M,  Russell ML,  Moss L, Fonseca K, Fox J, Earn DJ, et al. Effect of inﬂuenza vac-
cination of children on infection rates in Hutterite communities: a randomized
trial. JAMA 2010;303(10):943–50.
[9] Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, et al. Uptake
and  impact of a new live attenuated inﬂuenza vaccine programme in England:
early results of a pilot in primary school-age children, 2013/14 inﬂuenza season.
Euro Surveill 2014;19(22):20823.
10] Moran K, Maaten S, Guttmann A, Northrup D, Kwong JC. Inﬂuenza vaccina-
tion rates in Ontario children: implications for universal childhood vaccination
policy. Vaccine 2009;27(17):2350–5.
11] Kwong JC, Ge H,  Rosella LC, Guan J, Maaten S, Moran K, et al. School-based
inﬂuenza vaccine delivery, vaccination rates, and healthcare use in the context
of  a universal inﬂuenza immunization program: an ecological study. Vaccine
2010;28(15):2722–9.
12] National Vaccine Advisory Committee. The promise and challenge of adolescent
immunization. Am J Prev Med  2008;35(2):152–7.
13] Sales JM,  Painter JE, Pazol K, Gargano LM,  Orenstein W,  Hughes JM,  et al. Rural
parents’ vaccination-related attitudes and intention to vaccinate middle and
high school children against inﬂuenza following educational inﬂuenza vacci-
nation intervention. Hum Vaccin 2011;7(11):1146–52.
14] Painter JE, Sales JM,  Pazol K, Wingood GM,  Windle M,  Orenstein WA,  et al.
Adolescent attitudes toward inﬂuenza vaccination and vaccine uptake in a
school-based inﬂuenza vaccination intervention: a mediation analysis. J Sch
Health 2011;81(6):304–12.
15] Ontario Ministry of Health and Long-Term Care. Immunization: school age chil-
dren. Ontario: Ontario Ministry of Health and Long-Term Care; 2014. 〈http://
www.health.gov.on.ca/en/public/programs/immunization/school age.aspx〉
(accessed 2014 Sep 8).
16] MacDougall D, Crowe L, Pereira JA, Kwong JC, Quach S, Wormsbecker AE,
et  al. Parental perceptions of school-based inﬂuenza immunisation in Ontario,
Canada: a qualitative study. BMJ  Open 2014;4(6):e005189 (2014-005189).
17] National Advisory Committee on Immunization (NACI). Statement on seasonal
inﬂuenza vaccine for 2011–2012. Can Commun Dis Rep 2011;37(ACS-5):1–55.
18] Rhorer J, Ambrose CS, Dickinson S, Hamilton H,  Oleka NA, Malinoski FJ, et al.
Efﬁcacy of live attenuated inﬂuenza vaccine in children: a meta-analysis of nine
randomized clinical trials. Vaccine 2009;27(7):1101–10.
19] Poehling KA, Talbot HK, Williams JV, Zhu Y, Lott J, Patterson L, et al. Impact of a
school-based inﬂuenza immunization program on disease burden: comparison
of  two Tennessee counties. Vaccine 2009;27(20):2695–700.
20] du Plessis V, Beshiri R, Bollman R. Deﬁnitions of rural. Rural Small-Town Can
Anal Bull 2001;3(3):1–17.
21] Bland JM, Kerry SM.  Statistics notes. Weighted comparison of means. BMJ
1998;316(7125):129.
22] Guest G, MacQueen KM,  Namey EE. Applied thematic analysis. Thousand Oaks,
CA: Sage Publications Inc.; 2012.
23] King Jr JC, Stoddard JJ, Gaglani MJ,  Moore KA, Magder L, McClure E,
et  al. Effectiveness of school-based inﬂuenza vaccination. N Engl J Med
2006;355(24):2523–32.
24] Tarride JE, Burke N, Von Keyserlingk C, O’Reilly D, Xie F, Goeree R. Cost-
effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus
injectable inactivated inﬂuenza vaccine (TIV) for Canadian children and ado-
lescents. Clinicoecon Outcomes Res 2012;4:287–98.
25] Rose MA,  Stoermann J, Bittner-Brewe J, Rosewich M,  Eickmeier O,  et al. Effec-
tiveness, tolerability and patient satisfaction of paediatric live-attenuated
inﬂuenza immunization (LAIV) in routine-care in Germany: a case-control
study. Trials Vaccinol 2013;2:49–52.
26] Flood EM,  Ryan KJ, Rousculp MD,  Beusterien KM,  Block SL, Hall MC,  et al.
A  survey of children’s preferences for inﬂuenza vaccine attributes. Vaccine
2011;29(26):4334–40.27] Ambrose CS, Sifakis F. Factors associated with increased vaccination in
2009 H1N1 school-located inﬂuenza vaccination programs. Hum Vaccin
2011;7(8):864–7.
28] Lind C, Russell ML,  MacDonald J, Collins R, Frank CJ, Davis AE. School-based
inﬂuenza vaccination: parents’ perspectives. PLoS One  2014;9(3):e93490.
